The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Debt | Alive

Total Raised


Last Raised

$4M | 14 yrs ago

About ProteoGenix

ProteoGenix offers maternal-fetal diagnostics

ProteoGenix Headquarter Location

3545 Howard Way Floor 1

Costa Mesa, California, 92626,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest ProteoGenix News

ProteoGenix Doubles R&D Facilities to Pave the Way for Minimal Animal Use in Biologics Development

Jul 7, 2022

News provided by ProteoGenix on Thursday 7th Jul 2022 “Our rapid growth results from our relentless focus on biologics developability and our commitment to innovation. New facilities support the fast growth and expansion of the phage display, antibody development, and bioproduction platforms Schiltigheim, France: ProteoGenix , a contract research organization specializing in biologics discovery and bioproduction, is pleased to announce the expansion of its offices and R&D facilities in the north of Strasbourg, France. After a fast growth of 50-100% per year in the past three years, the company has relocated within the “Espace Européen de l’Entreprise” (E3), one of the most attractive business parks in Eastern France, and house to 550 companies. The new facilities double the company’s R&D capacity and accommodate a reformed phage display and mammalian bioproduction research hub, showcasing ProteoGenix’s commitment to reducing time to market while minimizing animal use. In the coming months, the increased capabilities will also create dozens of new biotechnology-related jobs. “The expansion of our R&D department marks an important milestone towards making biologics development more efficient and less dependent on animal use,” said Dr. Raphaël Hopfner, co-founder and chief scientific officer at ProteoGenix. “Not only will we be able to increase our capabilities in terms of contract services, but we will also do so while expanding our in-house research programs in innovative cell and bioproduction process engineering, phage display development, and antibody sequencing and engineering.” “Our rapid growth results from our relentless focus on biologics developability and our commitment to innovation,” said Philippe Funfrock, co-founder and CEO of ProteoGenix. “We are excited about the future and look forward to working with our partners to bring better biologics to the market.” Launched in 2003 and approaching its 20th anniversary, ProteoGenix continues to invest in the development of its phage display platform allied with ultra-high diversity antibody libraries, the establishment of a new antibody next-generation sequencing platform, and the development of scalable bioproduction solutions, from the large to the ultra-small scale. Recently, the company developed the first COVID-19 human antibody library, created the market’s most diverse nanobody and canine antibody libraries, launched an ultra-high yield and cost-effective transient expression kit (XtenCHO™), and collaborated with Aseem Healthcare and Trident Biopharm Solutions to generate a new broadly neutralizing human antibody cocktail to treat the COVID-19 disease. About ProteoGenix ProteoGenix is a France-based biotech contract research organization (CRO) providing flexible end-to-end solutions for the discovery and development of life-saving biologics, precision diagnostic tools, and robust reagents for research. As a global leader in antibody, protein, peptide, and gene production, ProteoGenix aims at fostering the development of next-generation immunotherapies by focusing on developability. For more information, please visit . Press release distributed by Pressat on behalf of ProteoGenix, on Thursday 7 July, 2022. For more information subscribe and follow

  • When was ProteoGenix founded?

    ProteoGenix was founded in 2002.

  • Where is ProteoGenix's headquarters?

    ProteoGenix's headquarters is located at 3545 Howard Way, Costa Mesa.

  • What is ProteoGenix's latest funding round?

    ProteoGenix's latest funding round is Debt.

  • How much did ProteoGenix raise?

    ProteoGenix raised a total of $24M.

  • Who are the investors of ProteoGenix?

    Investors of ProteoGenix include New Leaf Venture Partners, TPG Growth, Burrill & Company and Kaiser Permanente Ventures.

  • Who are ProteoGenix's competitors?

    Competitors of ProteoGenix include Affidea, Biodesix, Signature Diagnostics, Allegro Diagnostics, Pathwork Diagnostics and 13 more.

You May Also Like


AngioLogix is a provider of cardiovascular health diagnostics.

Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.


LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.